FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206344722> ?p ?o ?g. }

• W3206344722 abstract "Background Although immune checkpoint inhibitors (ICIs) combined with vascular endothelial growth factor receptor (VEGFR)-targeted therapy and sunitinib monotherapy have been widely applied to metastatic renal cell carcinoma (mRCC), effectiveness and safety data are still lacking. To optimize clinical decision-making, we conducted a systematic review and meta-analysis of published randomized clinical trials to characterize the efficacy and the risk of adverse events (AEs) in patients treated with ICIs plus anti-VEGF therapy. Materials and Methods We used PubMed, EMBASE, and the Cochrane Library to retrieve randomized controlled trials (RCTs) published before March 27, 2021. The efficacy outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). The pooled risk ratio (RR) and 95% confidence intervals (CI) of AEs were calculated in the safety analysis. Results Six RCTs involving 4,227 patients were identified after a systematic search. For OS, ICI and anti-VEGF combination therapy decreased mortality approximately 30% in the intention-to-treat population (ITT) (hazard ratio (HR) = 0.70, 95% CI: 0.57–0.87), but there was no statistical difference in patients evaluated as “favorable” by the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) criteria compared with monotherapy (HR = 0.90, 95% CI: 0.55–1.46, p = 0.66). In terms of PFS, the progression risk for all participants declined 35% (HR = 0.65, 95% CI: 0.50–0.83) and patients evaluated as “poor” by IMDC benefited further (HR = 0.46, 95% CI: 0.36–0.58). No evident divergence was found in age and sex subgroups. The RRs of all-grade hypertension, arthralgia, rash, proteinuria, high-grade (grades 3–5) arthralgia, and proteinuria developed after combination therapy were increased compared with sunitinib. The risk of high-grade hypertension and rash showed no statistical difference. However, the risk of hand-foot skin reaction (HFSR), stomatitis, and dysgeusia decreased in combination therapy groups. Conclusions Compared with sunitinib, OS, PFS, and ORR were significantly improved in patients receiving ICI and anti-VEGF combination therapy at the expense of increased specific AEs. More attention should be paid to individualized application of these combination therapies to achieve the best benefit-risk ratio in the clinic. Systematic Review Registration [ https://inplasy.com/ ] INPLASY: 202130104." @default.
• W3206344722 created "2021-10-25" @default.
• W3206344722 creator A5002240897 @default.
• W3206344722 creator A5035281531 @default.
• W3206344722 creator A5051002345 @default.
• W3206344722 creator A5067799719 @default.
• W3206344722 creator A5070332636 @default.
• W3206344722 creator A5085576539 @default.
• W3206344722 creator A5086326013 @default.
• W3206344722 date "2021-10-14" @default.
• W3206344722 modified "2023-10-14" @default.
• W3206344722 title "Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis" @default.
• W3206344722 cites W1562056707 @default.
• W3206344722 cites W1665341330 @default.
• W3206344722 cites W1882924936 @default.
• W3206344722 cites W1964435302 @default.
• W3206344722 cites W1965024282 @default.
• W3206344722 cites W1965372054 @default.
• W3206344722 cites W1970263079 @default.
• W3206344722 cites W1974789470 @default.
• W3206344722 cites W1991515868 @default.
• W3206344722 cites W1998776115 @default.
• W3206344722 cites W2035783858 @default.
• W3206344722 cites W2074415344 @default.
• W3206344722 cites W2081376995 @default.
• W3206344722 cites W2108606306 @default.
• W3206344722 cites W2109348840 @default.
• W3206344722 cites W2111743784 @default.
• W3206344722 cites W2117200377 @default.
• W3206344722 cites W2150575159 @default.
• W3206344722 cites W2157823046 @default.
• W3206344722 cites W2180006680 @default.
• W3206344722 cites W2277947482 @default.
• W3206344722 cites W2317191553 @default.
• W3206344722 cites W2329871425 @default.
• W3206344722 cites W2342038157 @default.
• W3206344722 cites W2343144688 @default.
• W3206344722 cites W2560219063 @default.
• W3206344722 cites W2560367415 @default.
• W3206344722 cites W2734522096 @default.
• W3206344722 cites W2743419024 @default.
• W3206344722 cites W2768713849 @default.
• W3206344722 cites W2783142536 @default.
• W3206344722 cites W2792937256 @default.
• W3206344722 cites W2805302875 @default.
• W3206344722 cites W2908235708 @default.
• W3206344722 cites W2911812451 @default.
• W3206344722 cites W2913745075 @default.
• W3206344722 cites W2915729824 @default.
• W3206344722 cites W2943887705 @default.
• W3206344722 cites W2991268660 @default.
• W3206344722 cites W3000015829 @default.
• W3206344722 cites W3003641482 @default.
• W3206344722 cites W3004222956 @default.
• W3206344722 cites W3009123791 @default.
• W3206344722 cites W3014505556 @default.
• W3206344722 cites W3025806849 @default.
• W3206344722 cites W3049325142 @default.
• W3206344722 cites W3071575475 @default.
• W3206344722 cites W3083155301 @default.
• W3206344722 cites W3092223743 @default.
• W3206344722 cites W3092634387 @default.
• W3206344722 cites W3093923068 @default.
• W3206344722 cites W3096713247 @default.
• W3206344722 cites W3109408450 @default.
• W3206344722 cites W3131063362 @default.
• W3206344722 cites W3134702367 @default.
• W3206344722 cites W3134949580 @default.
• W3206344722 doi "https://doi.org/10.3389/fonc.2021.739263" @default.
• W3206344722 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8552014" @default.
• W3206344722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34722290" @default.
• W3206344722 hasPublicationYear "2021" @default.
• W3206344722 type Work @default.
• W3206344722 sameAs 3206344722 @default.
• W3206344722 citedByCount "5" @default.
• W3206344722 countsByYear W32063447222022 @default.
• W3206344722 countsByYear W32063447222023 @default.
• W3206344722 crossrefType "journal-article" @default.
• W3206344722 hasAuthorship W3206344722A5002240897 @default.
• W3206344722 hasAuthorship W3206344722A5035281531 @default.
• W3206344722 hasAuthorship W3206344722A5051002345 @default.
• W3206344722 hasAuthorship W3206344722A5067799719 @default.
• W3206344722 hasAuthorship W3206344722A5070332636 @default.
• W3206344722 hasAuthorship W3206344722A5085576539 @default.
• W3206344722 hasAuthorship W3206344722A5086326013 @default.
• W3206344722 hasBestOaLocation W32063447221 @default.
• W3206344722 hasConcept C126322002 @default.
• W3206344722 hasConcept C143998085 @default.
• W3206344722 hasConcept C168563851 @default.
• W3206344722 hasConcept C197934379 @default.
• W3206344722 hasConcept C207103383 @default.
• W3206344722 hasConcept C2776694085 @default.
• W3206344722 hasConcept C2777472916 @default.
• W3206344722 hasConcept C2779490328 @default.
• W3206344722 hasConcept C2780739268 @default.
• W3206344722 hasConcept C2908647359 @default.
• W3206344722 hasConcept C44249647 @default.
• W3206344722 hasConcept C71924100 @default.
• W3206344722 hasConcept C82789193 @default.
• W3206344722 hasConcept C95190672 @default.

• next